Description
This advanced kit utilizes Air-Liquid Interface (ALI) technology to construct lung cancer organoids that closely mimic the in vivo tumor immune microenvironment. By retaining native tumor-infiltrating lymphocytes (TILs), stroma, and intrinsic T-cell receptor repertoires, it provides an unparalleled in vitro model for studying immune checkpoint blockades and personalized immunotherapies. Optimized reagents ensure highly efficient ALI model establishment.